Immutep Limited provided an update on its TACTI-002 and AIPAC studies for its lead product candidate, eftilagimod alpha ("efti" or "IMP321"). The requisite number of predefined patient responses was observed in stage 1 of Part C. The decision by the DMC to recommend opening stage 2 recruitment follows its review of preliminary safety and efficacy data and is based on a predefined efficacy threshold. This allows the company to proceed with the recruitment of an additional 19 patients, forming stage 2 of Part C of the study, having also completed recruitment of the 18 HNSCC patients for stage 1. The staged approach to patient enrolment is based on the study's Simon's two-stage clinical trial design. Recruitment is ongoing for Part B (second line NSCLC) with 10 out of 23 patients now participating, and for stage 2 of Part A (first line NSCLC), where 4 out of 19 patients are now participating. The Company expects to report more mature data from TACTI-002 in First Quarter CY20. The Company continues to progress its AIPAC trial which evaluates efti in combination with chemotherapy in 227 metastatic breast cancer patients in a randomized, double blinded, placebo-controlled phase IIb clinical trial.